A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Postmenopausal Women With High-Risk Early Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2034-01-01

Target enrollment:

Participant gender:

The study is being conducted to evaluate the efficacy and safety of HRS-8080 in postmenopausal women with high-risk early breast cancer.

PHASE3

Shandong Suncadia Medicine Co., Ltd.

Letrozole
Tamoxifen